There are currently 127 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
NCT00018057
Recruiting
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be s... Read More
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
05/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Anxiety Disorders
Register for Updates
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
NCT05630963
Recruiting
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/06/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Invasive Decoding and Stimulation of Altered Reward Computations in Depression
NCT05239780
Recruiting
Novel invasive neurostimulation stimulation strategies through neurosurgical interventions are emerging as a promising therapeutical strategy for major depressive disorder. These have been applied mostly to the anterior cingulate cortex, but other limbic brain regions have shown promise as anatomical targets for new neurostimulation strategies. The researchers seek to study neural activity in limbic brain areas implicated in decision behavior and mood regulation to identify novel targets for tre... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/06/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
NCT06247839
Recruiting
This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/05/2025
Locations: Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Neural Correlates of Stress and Perceived Control in Adolescent Depression
NCT04788524
Recruiting
Lack of perceived control, particularly during stress, has been critically implicated in major depressive disorder (MDD) and anhedonic symptoms, especially among female adolescents; yet the neural underpinnings of perceived control disruptions in MDD remain poorly understood. Using functional magnetic resonance imaging with a novel "value of control task" in conjunction with a prospective design, this study will provide a comprehensive understanding of stress and perceived control related mechan... Read More
Gender:
FEMALE
Ages:
Between 14 years and 18 years
Trial Updated:
05/05/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Major Depressive Disorder
Register for Updates
Testing a Transdiagnostic TMS Treatment Target
NCT06282146
Recruiting
The goal of this clinical trial is to test a new brain stimulation treatment target for individuals with depression plus at least one additional psychiatric disorder. The main question is to understand the safety profile of a non-invasive form of brain stimulation called accelerated intermittent theta burst stimulation when it is targeting the posterior parietal cortex. Additional questions focus on whether this stimulation improves symptoms of depression and other psychiatric disorders as well... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Depression, Psychiatric Disorder, Mood Disorders, Mental Disorder, Anxiety Disorders, OCD, PTSD
Register for Updates
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335
Recruiting
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objective: Main Study: To study the effects of ketamine in treating depression. Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry. To study how ketamine effects the brain. This... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/02/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer, Major Depressive Disorder, Depression
Register for Updates
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/01/2025
Locations: Reverie Mind, LLC, Chandler, Arizona +67 locations
Conditions: Major Depressive Disorder
Register for Updates
Natural History of Depression, Bipolar Disorder and Suicide Risk
NCT06462196
Recruiting
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medica... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Register for Updates
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Neurocrine Clinical Site, Saint Charles, Missouri
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/29/2025
Locations: Neumora Investigator site, Huntsville, Alabama +147 locations
Conditions: Major Depressive Disorder
Register for Updates
IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
NCT04629599
Recruiting
This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
04/28/2025
Locations: Anywhere in the entire state of Michigan (treatment is virtual), Flint, Michigan
Conditions: Major Depressive Disorder
Register for Updates